Home › Filings & Releases › April 2026

Filings & Releases — April 2026

783 documents from 246 companies (25 releases) · updated Nov 7, 2026

Company

All filings (+419)

Thursday, April 3094

ZURAZura BioDEF 14AProxy statement
ZURAZura BioARSAnnual report to shareholders
ZNTLZentalis PharmaceuticalsDEFA14AProxy soliciting material
ZNTLZentalis PharmaceuticalsDEF 14AProxy statement
ZNTLZentalis PharmaceuticalsARSAnnual report to shareholders
WVEWave Life SciencesUPLOADUPLOAD
WVEWave Life Sciences10-K/AAnnual report (amended)
VKTXViking TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
VKTXViking Therapeutics10-QQuarterly report
UNCYUnicycive TherapeuticsDEFA14AProxy soliciting material
UNCYUnicycive TherapeuticsDEF 14AProxy statement
UNCYUnicycive TherapeuticsARSAnnual report to shareholders
TVTXTravere TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
TLSATiziana Life SciencesNT 20-FNT 20-F
TGTXTg TherapeuticsDEF 14AProxy statement
SRPTSarepta TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
SNDXSyndax PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
SNDXSyndax PharmaceuticalsDEFA14AProxy soliciting material
SNDXSyndax PharmaceuticalsDEF 14AProxy statement
SNDXSyndax PharmaceuticalsARSAnnual report to shareholders
SNDXSyndax Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
SNDXSyndax Pharmaceuticals10-QQuarterly report
SMMTSummit TherapeuticsReleaseShare on Facebook (opens in new window)
SMMTSummit TherapeuticsReleaseShare on Linkedin (opens in new window)
SMMTSummit TherapeuticsReleaseShare on Twitter (opens in new window)
SMMTSummit TherapeuticsReleaseShare on Whatsapp (opens in new window)
SMMTSummit Therapeutics8-KCurrent report: results of operations · EX-99.1
SMMTSummit Therapeutics10-QQuarterly report
SEPNSepternaDEFA14AProxy soliciting material
SEPNSepternaDEF 14AProxy statement
SEPNSepternaARSAnnual report to shareholders
SCYXScynexisDEFA14AProxy soliciting material
SCYXScynexisDEF 14AProxy statement
SCYXScynexisARSAnnual report to shareholders
SABSSAB BiotherapeuticsDEF 14AProxy statement
RYTMRhythm PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
RXRXRecursion PharmaceuticalsDEFA14AProxy soliciting material
RXRXRecursion PharmaceuticalsDEF 14AProxy statement
RXRXRecursion PharmaceuticalsARSAnnual report to shareholders
RXRXRecursion Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
RNTXRein TherapeuticsEFFECTRegistration effective
RNACCartesian TherapeuticsS-8Employee plan registration
RNACCartesian Therapeutics8-KCurrent report: results of operations · EX-99.1
RNACCartesian Therapeutics10-QQuarterly report
RAREUltragenyx PharmaceuticalDEFA14AProxy soliciting material
QUREuniQureSCHEDULE 13G/A13G amendment
QUREuniQure8-KCurrent report: Reg FD disclosure · EX-99.1
QTTBQ32 BioDEFA14AProxy soliciting material
QTTBQ32 BioDEF 14AProxy statement
QTTBQ32 BioARSAnnual report to shareholders
PTGXProtagonist TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
PCVXVaxcyteSCHEDULE 13GPassive >5% holder (13G)
PCSAProcessa Pharmaceuticals8-KCurrent report: officer / director change
PCSAProcessa Pharmaceuticals10-K/AAnnual report (amended)
ORKAOruka Therapeutics8-KCurrent report: results of operations, other events · EX-99.1 EXCERPT FROM PRELIMINARY PROSPECTUS SUPPLEMENT DATED APRIL 27, 2026
OMEROmerosDEF 14AProxy statement
OMEROmerosARSAnnual report to shareholders
OKUROnKure TherapeuticsUPLOADUPLOAD
OKUROnKure TherapeuticsCORRESPCORRESP
NTLAIntellia TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
NTLAIntellia TherapeuticsDEFA14AProxy soliciting material
NTLAIntellia TherapeuticsDEF 14AProxy statement
NTLAIntellia TherapeuticsARSAnnual report to shareholders
NTLAIntellia Therapeutics8-KCurrent report: material agreement, results of operations
MISTMilestone PharmaceuticalsDEFA14AProxy soliciting material
MISTMilestone PharmaceuticalsDEF 14AProxy statement
MISTMilestone PharmaceuticalsARSAnnual report to shareholders
MGTXMeiraGTxDEFA14AProxy soliciting material
MGTXMeiraGTxDEF 14AProxy statement
MGTXMeiraGTxARSAnnual report to shareholders
MESOMesoblast6-KForeign issuer report · EX-99.1
MDNAFMedicenna TherapeuticsReleaseMedicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
LXEOLexeo TherapeuticsDEFA14AProxy soliciting material
LXEOLexeo TherapeuticsDEF 14AProxy statement
LXEOLexeo TherapeuticsARSAnnual report to shareholders
LXEOLexeo Therapeutics8-KCurrent report: officer / director change
LRMRLarimar TherapeuticsSCHEDULE 13G/A13G amendment
LRMRLarimar TherapeuticsReleaseLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
KYMRKymera Therapeutics8-KCurrent report: results of operations · EX-99.1
KYMRKymera Therapeutics10-QQuarterly report
KURAKura OncologySCHEDULE 13GPassive >5% holder (13G)
KPRXKiora PharmaceuticalsDEF 14AProxy statement
IPSCCentury TherapeuticsReleaseCentury Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
IONSIonis PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
INSMInsmedSCHEDULE 13GPassive >5% holder (13G)
INKTMiNK TherapeuticsDEF 14AProxy statement
INKTMiNK TherapeuticsARSAnnual report to shareholders
IMUXImmunicS-3/AShelf registration (amended)
IDYAIDEAYA BiosciencesDEFA14AProxy soliciting material
IBRXImmunityBioDEFA14AProxy soliciting material
IBRXImmunityBioDEF 14AProxy statement
IBRXImmunityBioARSAnnual report to shareholders
HURATuHURA Biosciences8-K/ACurrent report (amended): other events · EX-99.1
HURATuHURA Biosciences10-K/AAnnual report (amended)
HELPHelus Pharma6-KForeign issuer report · EX-99.1
GLSIGreenwich LifeSciencesReleaseGreenwich LifeSciences Provides Update Regarding Form 10-K Filing
GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
FHTXFoghorn TherapeuticsDEFA14AProxy soliciting material
FHTXFoghorn TherapeuticsDEF 14AProxy statement
FHTXFoghorn TherapeuticsARSAnnual report to shareholders
ELDNEledon PharmaceuticalsDEFA14AProxy soliciting material
ELDNEledon PharmaceuticalsDEF 14AProxy statement
ELDNEledon PharmaceuticalsARSAnnual report to shareholders
DRTSAlpha Tau MedicalUPLOADUPLOAD
DRTSAlpha Tau MedicalCORRESPCORRESP
DBVTDBV Technologies8-KCurrent report: results of operations · EX-99.1
DBVTDBV Technologies10-QQuarterly report
DBVTDBV Technologies10-K/AAnnual report (amended)
CYDYCytoDyn8-KCurrent report: Reg FD disclosure · EX-99.1
CTNMContineum TherapeuticsDEFA14AProxy soliciting material
CTNMContineum TherapeuticsDEF 14AProxy statement
CTNMContineum TherapeuticsARSAnnual report to shareholders
CTNMContineum Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
CTMXCytomX TherapeuticsDEFA14AProxy soliciting material
CTMXCytomX TherapeuticsDEF 14AProxy statement
CRVOCervoMedDEF 14AProxy statement
CRVOCervoMedARSAnnual report to shareholders
CLRBCellectar Biosciences10-K/AAnnual report (amended)
BCYCBicycle Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
BCYCBicycle Therapeutics10-QQuarterly report
BBOTBridgeBio Oncology TherapeuticsPOS AMPost-effective amendment
AXSMAxsome Therapeutics8-KCurrent report: other events · EX-99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ARTVArtiva Biotherapeutics10-K/AAnnual report (amended)
ARDXArdelyx8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
ARDXArdelyx10-QQuarterly report
ALTAltimmuneSCHEDULE 13GPassive >5% holder (13G)
ALLOAllogene TherapeuticsDEFA14AProxy soliciting material
ALLOAllogene TherapeuticsDEF 14AProxy statement
ALLOAllogene TherapeuticsARSAnnual report to shareholders
ACRVAcrivon TherapeuticsDEFA14AProxy soliciting material
ACRVAcrivon TherapeuticsDEF 14AProxy statement
ACRVAcrivon TherapeuticsARSAnnual report to shareholders
ACIUAC Immune6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ACIUAC Immune6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ACHVAchieve Life Sciences10-K/AAnnual report (amended)

Wednesday, April 2955

Tuesday, April 2864

WVEWave Life Sciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
WVEWave Life Sciences10-QQuarterly report
VYGRVoyager TherapeuticsDEFA14AProxy soliciting material
VYGRVoyager TherapeuticsDEF 14AProxy statement
VYGRVoyager TherapeuticsARSAnnual report to shareholders
VTVTvTv TherapeuticsDEF 14AProxy statement
TARAProtara TherapeuticsDEFA14AProxy soliciting material
TARAProtara TherapeuticsDEF 14AProxy statement
TARAProtara TherapeuticsARSAnnual report to shareholders
SPRBSpruce BiosciencesSCHEDULE 13GPassive >5% holder (13G)
SGMTSagimet Biosciences8-KCurrent report: material agreement
SGMTSagimet Biosciences424B5Prospectus supplement (offering)
SCYXScynexisSCHEDULE 13GPassive >5% holder (13G)
RVMDRevolution MedicinesDEFA14AProxy soliciting material
RVMDRevolution MedicinesARSAnnual report to shareholders
RNTXRein TherapeuticsS-1Registration statement
RNTXRein TherapeuticsCORRESPCORRESP
RNTXRein TherapeuticsCORRESPCORRESP
RNACCartesian TherapeuticsDEFA14AProxy soliciting material
RNACCartesian TherapeuticsDEF 14AProxy statement
RLAYRelay TherapeuticsDEFA14AProxy soliciting material
RLAYRelay TherapeuticsDEF 14AProxy statement
RLAYRelay TherapeuticsARSAnnual report to shareholders
RCKTRocket Pharmaceuticals8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
PTGXProtagonist TherapeuticsDEFA14AProxy soliciting material
PTGXProtagonist TherapeuticsDEF 14AProxy statement
PTGXProtagonist TherapeuticsARSAnnual report to shareholders
PRLDPrelude TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
PEPGPepGenDEFA14AProxy soliciting material
PEPGPepGenDEF 14AProxy statement
PEPGPepGenARSAnnual report to shareholders
ORICOric PharmaceuticalsDEFA14AProxy soliciting material
ORICOric PharmaceuticalsDEF 14AProxy statement
ORICOric PharmaceuticalsARSAnnual report to shareholders
OCGNOcugenDEFA14AProxy soliciting material
OCGNOcugenDEF 14AProxy statement
OCGNOcugenARSAnnual report to shareholders
NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED APRIL 28, 2026
MAZEMaze TherapeuticsDEFA14AProxy soliciting material
MAZEMaze TherapeuticsDEF 14AProxy statement
MAZEMaze TherapeuticsARSAnnual report to shareholders
LENZLENZ TherapeuticsDEFA14AProxy soliciting material
LENZLENZ TherapeuticsDEF 14AProxy statement
LENZLENZ TherapeuticsARSAnnual report to shareholders
JBIOJade BiosciencesDEFA14AProxy soliciting material
JBIOJade BiosciencesDEF 14AProxy statement
JBIOJade BiosciencesARSAnnual report to shareholders
JANXJanux TherapeuticsDEFA14AProxy soliciting material
JANXJanux TherapeuticsDEF 14AProxy statement
JANXJanux TherapeuticsARSAnnual report to shareholders
JANXJanux Therapeutics8-KCurrent report: officer / director change
IRONDisc MedicineDEFA14AProxy soliciting material
IRONDisc MedicineDEF 14AProxy statement
IRONDisc MedicineARSAnnual report to shareholders
IMUXImmunic8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
HELPHelus Pharma6-KForeign issuer report · EX-99.1
GANXGain TherapeuticsDEFA14AProxy soliciting material
GANXGain TherapeuticsDEF 14AProxy statement
GANXGain TherapeuticsARSAnnual report to shareholders
FDMT4D Molecular TherapeuticsDEFA14AProxy soliciting material
FDMT4D Molecular TherapeuticsDEF 14AProxy statement
FDMT4D Molecular TherapeuticsARSAnnual report to shareholders
FBIOFortress BiotechDEFA14AProxy soliciting material
FBIOFortress BiotechDEF 14AProxy statement
ERASErascaDEFA14AProxy soliciting material
ERASErascaDEF 14AProxy statement
ERASErascaARSAnnual report to shareholders
ELOXEloxx PharmaceuticalsPRE 14CPRE 14C
DRTSAlpha Tau MedicalF-3Shelf registration (foreign)
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 NEWS RELEASE DATED APRIL 28, 2026
CMMBChemomab Therapeutics6-KForeign issuer report
CLYMClimb Bio8-KCurrent report: material agreement, unregistered sale of equity, other events · EX-99.1
CINGCingulate424B3Prospectus (resale / update)
CGEMCullinan TherapeuticsS-3ASRAutomatic shelf registration
CGEMCullinan TherapeuticsDEFA14AProxy soliciting material
CGEMCullinan TherapeuticsDEF 14AProxy statement
CGEMCullinan TherapeuticsARSAnnual report to shareholders
CABACabaletta BioDEFA14AProxy soliciting material
CABACabaletta BioDEF 14AProxy statement
CABACabaletta BioARSAnnual report to shareholders
BMEABiomea Fusion8-KCurrent report: Reg FD disclosure, other events · EX-99.1
BBOTBridgeBio Oncology TherapeuticsDEFA14AProxy soliciting material
BBOTBridgeBio Oncology TherapeuticsDEF 14AProxy statement
BBOTBridgeBio Oncology TherapeuticsARSAnnual report to shareholders
ARVNArvinasSCHEDULE 13GPassive >5% holder (13G)
ANABAnaptysBio10-K/AAnnual report (amended)
AKBAAkebia TherapeuticsDEFA14AProxy soliciting material
AKBAAkebia TherapeuticsDEF 14AProxy statement
ACRSAclaris Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
ACETAdicet Bio8-KCurrent report: unregistered sale of equity

Monday, April 2761

XNCRXencorDEFA14AProxy soliciting material
XNCRXencorDEF 14AProxy statement
XNCRXencorARSAnnual report to shareholders
XNCRXencor8-KCurrent report: officer / director change
VORVor BiopharmaS-3Shelf registration
VORVor BiopharmaDEFA14AProxy soliciting material
VORVor BiopharmaDEF 14AProxy statement
VORVor BiopharmaARSAnnual report to shareholders
TARAProtara TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
TARAProtara TherapeuticsReleaseProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
TARAProtara TherapeuticsReleaseINVESTOR OVERVIEW
SMMTSummit TherapeuticsUPLOADUPLOAD
SLDBSolid BiosciencesSCHEDULE 13G/A13G amendment
SIONSionna TherapeuticsDEFA14AProxy soliciting material
SIONSionna TherapeuticsDEF 14AProxy statement
SIONSionna TherapeuticsARSAnnual report to shareholders
SGMTSagimet Biosciences8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
SGMTSagimet Biosciences8-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
SCYXScynexisDEF 14AProxy statement
RVMDRevolution MedicinesDEF 14AProxy statement
RNTXRein Therapeutics10-K/AAnnual report (amended)
RLAYRelay Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
RCKTRocket PharmaceuticalsSC TO-ISC TO-I
QUREuniQureDEFA14AProxy soliciting material
QUREuniQureDEF 14AProxy statement
QUREuniQureARSAnnual report to shareholders
OVIDOvid TherapeuticsDEFA14AProxy soliciting material
OVIDOvid TherapeuticsDEF 14AProxy statement
OVIDOvid TherapeuticsARSAnnual report to shareholders
OVIDOvid Therapeutics424B3Prospectus (resale / update)
ORKAOruka Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 PRESS RELEASE, DATED APRIL 27, 2026
ORKAOruka Therapeutics424B5Prospectus supplement (offering)
ORKAOruka Therapeutics424B5Prospectus supplement (offering)
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
NVCTNuvectis PharmaDEFA14AProxy soliciting material
NVCTNuvectis PharmaDEF 14AProxy statement
NTLAIntellia Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
NTLAIntellia Therapeutics424B5Prospectus supplement (offering)
NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
MAIAMAIA BiotechnologyDEFA14AProxy soliciting material
LENZLENZ TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 INVESTOR PRESENTATION DATED APRIL 27, 2026
KODKodiak SciencesSCHEDULE 13GPassive >5% holder (13G)
JBIOJade BiosciencesSCHEDULE 13G/A13G amendment
IPSCCentury TherapeuticsDEFA14AProxy soliciting material
IPSCCentury TherapeuticsDEF 14AProxy statement
GRCEGrace TherapeuticsSCHEDULE 13G/A13G amendment
GRCEGrace Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
EYPTEyePointDEFA14AProxy soliciting material
EYPTEyePointDEF 14AProxy statement
EWTXEdgewise TherapeuticsSCHEDULE 13D/A13D amendment
ETONEton Pharmaceuticals8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-700.
ERASErasca8-KCurrent report: other events
ERASErasca8-KCurrent report: Reg FD disclosure, other events
ELVNEnliven TherapeuticsDEFA14AProxy soliciting material
ELVNEnliven TherapeuticsDEF 14AProxy statement
ELVNEnliven TherapeuticsARSAnnual report to shareholders
ELDNEledon PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED APRIL 27, 2026
DFTXDefinium TherapeuticsDEFA14AProxy soliciting material
DFTXDefinium TherapeuticsDEF 14AProxy statement
CRVSCorvus PharmaceuticalsSCHEDULE 13G/A13G amendment
CMPXCompass Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 PRESS RELEASE
CHRSCoherus OncologySCHEDULE 13G/A13G amendment
CGTXCognition TherapeuticsDEFA14AProxy soliciting material
CGTXCognition TherapeuticsDEF 14AProxy statement
CGTXCognition TherapeuticsARSAnnual report to shareholders
CATXPerspective TherapeuticsSCHEDULE 13G/A13G amendment
CADLCandel TherapeuticsSCHEDULE 13G/A13G amendment
BMEABiomea FusionDEF 14AProxy statement
BMEABiomea FusionARSAnnual report to shareholders
BIOABioAge LabsSCHEDULE 13GPassive >5% holder (13G)
BCAXBicara TherapeuticsDEFA14AProxy soliciting material
BCAXBicara TherapeuticsDEF 14AProxy statement
BCAXBicara TherapeuticsARSAnnual report to shareholders
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATAIAtai BeckleyReleaseAtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Researchcompany site may be offline after the acquisition
ARDXArdelyxSCHEDULE 13G/A13G amendment
ANNXAnnexonDEFA14AProxy soliciting material
ANNXAnnexonDEF 14AProxy statement
ANNXAnnexonARSAnnual report to shareholders
ALDXAldeyra TherapeuticsDEFA14AProxy soliciting material
ALDXAldeyra TherapeuticsDEF 14AProxy statement
ALDXAldeyra TherapeuticsARSAnnual report to shareholders
ACRSAclaris TherapeuticsSCHEDULE 13G/A13G amendment
ACHVAchieve Life SciencesSCHEDULE 13DActivist / >5% holder (13D)

Friday, April 2452

Thursday, April 2355

ZURAZura Bio8-KCurrent report: officer / director change
XERSXeris BiopharmaDEFA14AProxy soliciting material
XERSXeris BiopharmaDEF 14AProxy statement
XERSXeris BiopharmaARSAnnual report to shareholders
VNDAVanda PharmaceuticalsDEFA14AProxy soliciting material
VNDAVanda PharmaceuticalsDEF 14AProxy statement
VNDAVanda PharmaceuticalsARSAnnual report to shareholders
TLXTelix PharmaceuticalsUPLOADUPLOAD
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
TECXTectonic Therapeutic8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
SLSSELLAS Life Sciences GroupDEFA14AProxy soliciting material
SLSSELLAS Life Sciences GroupDEF 14AProxy statement
SLSSELLAS Life Sciences GroupARSAnnual report to shareholders
SLDBSolid BiosciencesDEFA14AProxy soliciting material
SLDBSolid BiosciencesDEF 14AProxy statement
SLDBSolid BiosciencesARSAnnual report to shareholders
RAPPRapport TherapeuticsDEFA14AProxy soliciting material
RAPPRapport TherapeuticsDEF 14AProxy statement
RAPPRapport TherapeuticsARSAnnual report to shareholders
PTNPalatin TechnologiesSCHEDULE 13GPassive >5% holder (13G)
PRLDPrelude TherapeuticsSCHEDULE 13D/A13D amendment
PCVXVaxcyteDEFA14AProxy soliciting material
PCVXVaxcyteDEF 14AProxy statement
PCVXVaxcyteARSAnnual report to shareholders
OVIDOvid TherapeuticsUPLOADUPLOAD
OVIDOvid TherapeuticsCORRESPCORRESP
OTLKOutlook Therapeutics8-KCurrent report: unregistered sale of equity, other events
OTLKOutlook Therapeutics424B5Prospectus supplement (offering)
OMEROmerosSCHEDULE 13G/A13G amendment
NKTXNkartaDEFA14AProxy soliciting material
NKTXNkartaDEF 14AProxy statement
NKTXNkartaARSAnnual report to shareholders
NKTRNektar Therapeutics8-KCurrent report: material agreement, other events · EX-99.1
NKTRNektar Therapeutics424B5Prospectus supplement (offering)
MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
LBRXLB PharmaceuticalsDEFA14AProxy soliciting material
LBRXLB PharmaceuticalsDEF 14AProxy statement
LBRXLB PharmaceuticalsARSAnnual report to shareholders
KODKodiak SciencesARSAnnual report to shareholders
IONSIonis PharmaceuticalsDEFA14AProxy soliciting material
IONSIonis PharmaceuticalsDEF 14AProxy statement
IONSIonis PharmaceuticalsARSAnnual report to shareholders
INMBInmune BioDEF 14AProxy statement
INBXInhibrx BiosciencesDEFA14AProxy soliciting material
INBXInhibrx BiosciencesDEF 14AProxy statement
INBXInhibrx BiosciencesARSAnnual report to shareholders
IMUXImmunic8-KCurrent report: holder rights modified, charter / bylaws / fiscal year, other events · EX-99.1
HELPHelus Pharma6-KForeign issuer report · EX-99.1
GRCEGrace Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
GPCRStructure TherapeuticsDEF 14AProxy statement
GPCRStructure TherapeuticsARSAnnual report to shareholders
EWTXEdgewise TherapeuticsDEFA14AProxy soliciting material
EWTXEdgewise TherapeuticsDEF 14AProxy statement
EWTXEdgewise TherapeuticsARSAnnual report to shareholders
DYNDyne TherapeuticsDEFA14AProxy soliciting material
DYNDyne TherapeuticsDEF 14AProxy statement
DYNDyne TherapeuticsARSAnnual report to shareholders
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE (ACAPELLA CLINICAL TRIAL) DATED APRIL 23, 2026
CRVSCorvus Pharmaceuticals8-KCurrent report: officer / director change
COGTCogent BiosciencesDEFA14AProxy soliciting material
COGTCogent BiosciencesDEF 14AProxy statement
COGTCogent BiosciencesARSAnnual report to shareholders
CNTBConnect Biopharma8-KCurrent report: Reg FD disclosure, other events · EX-99.1
BCRXBiocryst PharmaceuticalsDEFA14AProxy soliciting material
BCRXBiocryst PharmaceuticalsDEF 14AProxy statement
BCRXBiocryst PharmaceuticalsARSAnnual report to shareholders
BBOTBridgeBio Oncology Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
BBOTBridgeBio Oncology Therapeutics424B3Prospectus (resale / update)
AMLXAmylyx PharmaceuticalsDEFA14AProxy soliciting material
AMLXAmylyx PharmaceuticalsDEF 14AProxy statement
AMLXAmylyx PharmaceuticalsARSAnnual report to shareholders
ALLOAllogene TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
AGMBAgomab Therapeutics20-FAnnual report (foreign)
ACRVAcrivon TherapeuticsSCHEDULE 13D/A13D amendment
ACRSAclaris TherapeuticsDEFA14AProxy soliciting material
ACRSAclaris TherapeuticsDEF 14AProxy statement
ACRSAclaris TherapeuticsARSAnnual report to shareholders
ABOSAcumen PharmaceuticalsDEFA14AProxy soliciting material
ABOSAcumen PharmaceuticalsDEF 14AProxy statement
ABOSAcumen PharmaceuticalsARSAnnual report to shareholders

Wednesday, April 2247

XENEXenon PharmaceuticalsDEFA14AProxy soliciting material
XENEXenon PharmaceuticalsDEF 14AProxy statement
XENEXenon PharmaceuticalsARSAnnual report to shareholders
VNDAVanda Pharmaceuticals8-KCurrent report: officer / director change · EX-99.1
TSHATaysha Gene TherapiesDEFA14AProxy soliciting material
TSHATaysha Gene TherapiesDEF 14AProxy statement
TSHATaysha Gene TherapiesARSAnnual report to shareholders
TENXTenax TherapeuticsDEFA14AProxy soliciting material
TENXTenax TherapeuticsDEF 14AProxy statement
TENXTenax TherapeuticsARSAnnual report to shareholders
TENXTenax Therapeutics8-KCurrent report: officer / director change, other events · EX-99.1
SYRESpyre TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
STROSutro BiopharmaDEFA14AProxy soliciting material
STROSutro BiopharmaDEF 14AProxy statement
STROSutro BiopharmaARSAnnual report to shareholders
STOKStoke TherapeuticsDEFA14AProxy soliciting material
STOKStoke TherapeuticsDEF 14AProxy statement
STOKStoke TherapeuticsARSAnnual report to shareholders
SPRBSpruce Biosciences8-KCurrent report: material agreement, other events · EX-99.1
SABSSAB Biotherapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
PRLDPrelude TherapeuticsSCHEDULE 13D/A13D amendment
PMVPPMV PharmaceuticalsDEFA14AProxy soliciting material
PMVPPMV PharmaceuticalsDEF 14AProxy statement
PMVPPMV PharmaceuticalsARSAnnual report to shareholders
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
MAZEMaze Therapeutics8-KCurrent report: other events · EX-99.1
MAZEMaze Therapeutics424B5Prospectus supplement (offering)
KYTXKyverna Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
KYTXKyverna Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
KTTAPasithea TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
KROSKeros TherapeuticsDEFA14AProxy soliciting material
KROSKeros TherapeuticsDEF 14AProxy statement
KROSKeros TherapeuticsARSAnnual report to shareholders
KODKodiak SciencesDEFA14AProxy soliciting material
KODKodiak SciencesDEF 14AProxy statement
JBIOJade Biosciences8-KCurrent report: officer / director change
IXHLIncannex HealthcareReleaseIncannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF APRIL 22, 2026
IRDOpus GeneticsEFFECTRegistration effective
IRDOpus Genetics8-KCurrent report: shareholder vote
IMUXImmunic10-K/AAnnual report (amended)
HURATuHURA Biosciences8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1
HELPHelus PharmaSCHEDULE 13G/A13G amendment
GLUEMonte Rosa TherapeuticsSCHEDULE 13G/A13G amendment
FATEFate TherapeuticsSCHEDULE 13D/A13D amendment
EVMNEvommuneUPLOADUPLOAD
EVMNEvommuneCORRESPCORRESP
DFTXDefinium Therapeutics8-KCurrent report: other events · EX-99.1
CYDYCytoDynS-1Registration statement
CUECue Biopharma8-KCurrent report: holder rights modified, charter / bylaws / fiscal year
CRVOCervoMedReleaseCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
CINGCingulateCORRESPCORRESP
CCCCC4 TherapeuticsSCHEDULE 13G/A13G amendment
BCYCBicycle TherapeuticsDEF 14AProxy statement
BCYCBicycle TherapeuticsARSAnnual report to shareholders
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATAIAtai BeckleyDEFA14AProxy soliciting material
ATAIAtai BeckleyDEF 14AProxy statement
ANTXAN2 TherapeuticsDEFA14AProxy soliciting material
ANTXAN2 TherapeuticsDEF 14AProxy statement
ANTXAN2 TherapeuticsARSAnnual report to shareholders
ALTAltimmuneS-3MEFS-3MEF
ALTAltimmune424B5Prospectus supplement (offering)
ACTUActuate TherapeuticsSCHEDULE 13G/A13G amendment
ABSIAbsciDEFA14AProxy soliciting material
ABSIAbsciDEF 14AProxy statement
ABSIAbsciARSAnnual report to shareholders

Tuesday, April 2139

XERSXeris Biopharma8-KCurrent report: officer / director change
WVEWave Life SciencesDEFA14AProxy soliciting material
WVEWave Life Sciences8-KCurrent report: other events · EX-99.1
VYGRVoyager Therapeutics8-KCurrent report: officer / director change
VORVor BiopharmaSCHEDULE 13D/A13D amendment
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
STROSutro BiopharmaSCHEDULE 13G/A13G amendment
STROSutro BiopharmaSCHEDULE 13GPassive >5% holder (13G)
SPRBSpruce Biosciences424B5Prospectus supplement (offering)
SGMTSagimet BiosciencesDEF 14AProxy statement
SGMTSagimet BiosciencesARSAnnual report to shareholders
SGMTSagimet Biosciences8-KCurrent report: officer / director change, other events
RCUSArcus BiosciencesDEFA14AProxy soliciting material
RCUSArcus BiosciencesDEF 14AProxy statement
RCUSArcus BiosciencesARSAnnual report to shareholders
RAPPRapport Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
PRLDPrelude Therapeutics8-KCurrent report: material agreement, other events · EX-99.1
PRLDPrelude Therapeutics424B5Prospectus supplement (offering)
OVIDOvid TherapeuticsS-3Shelf registration
OTLKOutlook Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
ORKAOruka Therapeutics424B7Prospectus supplement
OKUROnKure TherapeuticsDEFA14AProxy soliciting material
OKUROnKure TherapeuticsDEF 14AProxy statement
OKUROnKure TherapeuticsARSAnnual report to shareholders
OCSOculis Holding6-KForeign issuer report · EX-99.1
MLTXMoonLake ImmunotherapeuticsDEFA14AProxy soliciting material
MLTXMoonLake ImmunotherapeuticsDEF 14AProxy statement
MLTXMoonLake ImmunotherapeuticsARSAnnual report to shareholders
KPRXKiora PharmaceuticalsDForm D (exempt offering)
IRDOpus GeneticsS-3/AShelf registration (amended)
IRDOpus GeneticsCORRESPCORRESP
IONSIonis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
INBXInhibrx Biosciences8-KCurrent report: Reg FD disclosure, other events · EX-99.1
IMTXImmaticsReleaseImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
IMTXImmatics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
IMRXImmuneeringReleaseImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
FHTXFoghorn Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
EVMNEvommuneDEFA14AProxy soliciting material
EVMNEvommuneDEF 14AProxy statement
EVMNEvommuneARSAnnual report to shareholders
ERASErasca8-KCurrent report: other events
ELDNEledon PharmaceuticalsPRE 14APRE 14A
CBIOCrescent BiopharmaDEFA14AProxy soliciting material
CBIOCrescent BiopharmaDEFA14AProxy soliciting material
CBIOCrescent BiopharmaDEF 14AProxy statement
BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
BIOABioAge LabsDEFA14AProxy soliciting material
BIOABioAge LabsDEF 14AProxy statement
BIOABioAge LabsARSAnnual report to shareholders
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1

Monday, April 2034

VRCAVerrica PharmaceuticalsDEFA14AProxy soliciting material
VRCAVerrica PharmaceuticalsDEF 14AProxy statement
VRCAVerrica PharmaceuticalsARSAnnual report to shareholders
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
SYRESpyre TherapeuticsSCHEDULE 13D/A13D amendment
SPRBSpruce Biosciences424B5Prospectus supplement (offering)
SIONSionna TherapeuticsSCHEDULE 13D/A13D amendment
SCYXScynexisPRE 14APRE 14A
SCYXScynexis8-KCurrent report: officer / director change
RCUSArcus Biosciences8-KCurrent report: other events
PRLDPrelude Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
OVIDOvid Therapeutics8-KCurrent report: other events
OCGNOcugenPRER14APRER14A
NKTRNektar Therapeutics8-KCurrent report: Reg FD disclosure
NKTRNektar Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
NKTRNektar Therapeutics424B5Prospectus supplement (offering)
NGNENeurogene8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
NAMSNewAmsterdam PharmaPRE 14APRE 14A
LRMRLarimar TherapeuticsDEF 14AProxy statement
LRMRLarimar TherapeuticsARSAnnual report to shareholders
KYTXKyverna Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
IMRXImmuneeringReleaseImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
IMRXImmuneeringDEFA14AProxy soliciting material
IMRXImmuneeringDEF 14AProxy statement
HELPHelus Pharma6-KForeign issuer report · EX-99.1
HELPHelus Pharma6-KForeign issuer report · EX-99.1
CTMXCytomX TherapeuticsPRE 14APRE 14A
CHRSCoherus OncologyDEF 14AProxy statement
CHRSCoherus OncologyARSAnnual report to shareholders
CATXPerspective Therapeutics8-KCurrent report: other events · EX-99.1
CABACabaletta Bio8-KCurrent report: other events · EX-99.1
BCYCBicycle Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ANTXAN2 TherapeuticsEFFECTRegistration effective
ANTXAN2 Therapeutics424B5Prospectus supplement (offering)
ANTXAN2 Therapeutics424B3Prospectus (resale / update)
ANABAnaptysBio8-KCurrent report: material agreement, acquisition / disposition, officer / director change · EX-99.1
ALLOAllogene TherapeuticsPRE 14APRE 14A
ALDXAldeyra Therapeutics8-KCurrent report: officer / director change
ADCTADC TherapeuticsDEFA14AProxy soliciting material
ADCTADC TherapeuticsDEF 14AProxy statement
ABVXAbivax6-KForeign issuer report · EX-99.1

Friday, April 1727

Thursday, April 1624

Wednesday, April 1527

ZYMEZymeworksSCHEDULE 13GPassive >5% holder (13G)
WVEWave Life SciencesPRE 14APRE 14A
WVEWave Life SciencesDEFA14AProxy soliciting material
WVEWave Life Sciences8-KCurrent report: material agreement, other events · EX-99.1
VORVor BiopharmaSCHEDULE 13D/A13D amendment
TNGXTango Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
RVPHReviva Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
RVMDRevolution MedicinesFWPFree writing prospectus (offering terms)
RVMDRevolution Medicines424B5Prospectus supplement (offering)
RVMDRevolution Medicines424B5Prospectus supplement (offering)
RVMDRevolution Medicines305B2305B2
PRLDPrelude Therapeutics8-KCurrent report: officer / director change · EX-99.1
PEPGPepGenDRSDRS
MESOMesoblast6-KForeign issuer report · EX-99.1
MBRXMoleculin Biotech8-KCurrent report: shareholder vote
LGVNLongeveronCORRESPCORRESP
KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED APRIL 15, 2026
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
GPCRStructure Therapeutics8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
EXELExelixisDEFA14AProxy soliciting material
EXELExelixisDEF 14AProxy statement
ETONEton Pharmaceuticals8-KCurrent report: material agreement, debt / obligation
ELVNEnliven TherapeuticsPRE 14APRE 14A
DTILPrecision BiosciencesSCHEDULE 13G/A13G amendment
CMPSCOMPASS PathwaysDEF 14AProxy statement
CMPSCOMPASS PathwaysARSAnnual report to shareholders
AUTLAutolus TherapeuticsUPLOADUPLOAD
AUTLAutolus TherapeuticsUPLOADUPLOAD
AUTLAutolus TherapeuticsDEL AMDEL AM
AUTLAutolus TherapeuticsDEL AMDEL AM
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ANTXAN2 TherapeuticsUPLOADUPLOAD
ALLOAllogene Therapeutics8-KCurrent report: other events · EX-99.1
ALLOAllogene Therapeutics424B5Prospectus supplement (offering)
AKBAAkebia TherapeuticsPRE 14APRE 14A
ADMAAdma BiologicsDEFA14AProxy soliciting material
ADMAAdma BiologicsDEF 14AProxy statement
ADMAAdma BiologicsARSAnnual report to shareholders
ADCTADC Therapeutics424B3Prospectus (resale / update)

Tuesday, April 1414

TVTXTravere Therapeutics8-KCurrent report: other events
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
TLSATiziana Life Sciences6-KForeign issuer report · EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED APRIL 14, 2026
OCGNOcugenSCHEDULE 13GPassive >5% holder (13G)
MBRXMoleculin BiotechEFFECTRegistration effective
MBRXMoleculin Biotech424B3Prospectus (resale / update)
MBRXMoleculin Biotech10-K/AAnnual report (amended)
LGVNLongeveronUPLOADUPLOAD
LEGNLegend Biotech6-KForeign issuer report
LBRXLB PharmaceuticalsEFFECTRegistration effective
LBRXLB Pharmaceuticals424B3Prospectus (resale / update)
IMUXImmunic8-KCurrent report: shareholder vote, other events
HRMYHarmony Biosciences8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
CRDLCardiol Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
CNTBConnect BiopharmaSCHEDULE 13GPassive >5% holder (13G)
CINGCingulateS-3Shelf registration
CHRSCoherus OncologyDEFA14AProxy soliciting material
ABSIAbsciSCHEDULE 13D/A13D amendment

Monday, April 1329

XENEXenon PharmaceuticalsS-8Employee plan registration
XENEXenon Pharmaceuticals8-KCurrent report: officer / director change
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
SYRESpyre Therapeutics8-KCurrent report: results of operations, other events
SYRESpyre Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
SYRESpyre Therapeutics424B5Prospectus supplement (offering)
SEPNSepterna8-KCurrent report: Reg FD disclosure · EX-99.1
SANASana Biotechnology8-KCurrent report: other events
SANASana Biotechnology424B5Prospectus supplement (offering)
RVMDRevolution Medicines8-KCurrent report: other events
RVMDRevolution Medicines424B5Prospectus supplement (offering)
RVMDRevolution Medicines424B5Prospectus supplement (offering)
RLAYRelay TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
REPLReplimune Group8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
LXEOLexeo TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED APRIL 13, 2026
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KYTXKyverna TherapeuticsDEFA14AProxy soliciting material
KYTXKyverna TherapeuticsDEF 14AProxy statement
KYTXKyverna TherapeuticsARSAnnual report to shareholders
IDYAIDEAYA Biosciences8-KCurrent report: other events
EYPTEyePoint8-KCurrent report: other events · EX-99.1
EVMNEvommune8-KCurrent report: Reg FD disclosure · EX-99.1
CUECue Biopharma8-KCurrent report: shareholder vote
CGONCG Oncology8-KCurrent report: officer / director change
AUTLAutolus TherapeuticsS-3Shelf registration
AUTLAutolus TherapeuticsS-3Shelf registration
ALLOAllogene Therapeutics8-KCurrent report: other events
ALLOAllogene Therapeutics8-KCurrent report: other events
ALLOAllogene Therapeutics424B5Prospectus supplement (offering)
ACETAdicet BioSCHEDULE 13G/A13G amendment

Friday, April 1019

Thursday, April 919

ZNTLZentalis Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
VSTMVerastemDEF 14AProxy statement
VERAVera TherapeuticsDEFA14AProxy soliciting material
VERAVera TherapeuticsDEF 14AProxy statement
VERAVera TherapeuticsARSAnnual report to shareholders
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
SPRBSpruce BiosciencesDEFA14AProxy soliciting material
SPRBSpruce BiosciencesDEF 14AProxy statement
SPRBSpruce BiosciencesARSAnnual report to shareholders
RLMDRelmada TherapeuticsEFFECTRegistration effective
RLMDRelmada Therapeutics424B3Prospectus (resale / update)
PMNProMIS NeurosciencesDEFA14AProxy soliciting material
PMNProMIS NeurosciencesDEF 14AProxy statement
PMNProMIS NeurosciencesARSAnnual report to shareholders
IVVDInvivyd8-KCurrent report: other events · EX-99.1
IMUXImmunicS-8Employee plan registration
IDYAIDEAYA Biosciences8-KCurrent report: other events
IBRXImmunityBio8-KCurrent report: results of operations · EX-99.1
GOSSGossamer Bio8-KCurrent report: listing notice
FBRXForte Biosciences8-KCurrent report: material agreement, Reg FD disclosure, other events · EX-99.1
FBRXForte Biosciences424B5Prospectus supplement (offering)
DYNDyne TherapeuticsPRE 14APRE 14A
CHRSCoherus OncologyPRE 14APRE 14A
CCCCC4 Therapeutics8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
ANTXAN2 TherapeuticsS-3Shelf registration
ANTXAN2 Therapeutics8-KCurrent report: other events
ACTUActuate TherapeuticsARSAnnual report to shareholders

Wednesday, April 825

VORVor BiopharmaSCHEDULE 13D/A13D amendment
TENXTenax TherapeuticsSCHEDULE 13G/A13G amendment
SCYXScynexisSCHEDULE 13GPassive >5% holder (13G)
PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
PHIOPhio Pharmaceuticals8-KCurrent report: material agreement
PHIOPhio Pharmaceuticals424B5Prospectus supplement (offering)
ORKAOruka TherapeuticsCORRESPCORRESP
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechF-10POSF-10POS
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
ONCYOncolytics BiotechAWAW
NRIXNurix Therapeutics8-KCurrent report: results of operations · EX-99.1
NRIXNurix Therapeutics10-QQuarterly report
MLYSMineralys TherapeuticsDEFA14AProxy soliciting material
MLYSMineralys TherapeuticsDEF 14AProxy statement
MESOMesoblast6-KForeign issuer report · EX-99.1
MESOMesoblast6-KForeign issuer report · EX-99.1
MESOMesoblast6-KForeign issuer report · EX-99.1
MESOMesoblast6-KForeign issuer report · EX-99.1
MAIAMAIA BiotechnologyReleaseMAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
MAIAMAIA Biotechnology8-KCurrent report: other events · EX-99.1
LENZLENZ TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
KTTAPasithea TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
HURATuHURA Biosciences8-KCurrent report: officer / director change, other events · EX-99.1
HURATuHURA Biosciences424B5Prospectus supplement (offering)
FBRXForte BiosciencesReleaseForte Biosciences Announces Proposed Public Offeringcompany site may be offline after the acquisition
FBRXForte BiosciencesReleaseForte Biosciences Announces Pricing of $150 Million Public Offeringcompany site may be offline after the acquisition
FBRXForte Biosciences424B5Prospectus supplement (offering)
DTILPrecision BiosciencesDEFA14AProxy soliciting material
DTILPrecision BiosciencesDEF 14AProxy statement
DTILPrecision BiosciencesARSAnnual report to shareholders
CYDYCytoDyn424B3Prospectus (resale / update)
CYDYCytoDyn10-QQuarterly report
BCAXBicara TherapeuticsSCHEDULE 13G/A13G amendment
AUTLAutolus Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
APGEApogee TherapeuticsSCHEDULE 13G/A13G amendment

Tuesday, April 718

Monday, April 618

Friday, April 39

Thursday, April 223

ZBIOZenas BioPharmaSCHEDULE 13D/A13D amendment
VNDAVanda Pharmaceuticals8-KCurrent report: officer / director change
TYRATyra Biosciences8-KCurrent report: officer / director change
TTRXTurn TherapeuticsEFFECTRegistration effective
TTRXTurn TherapeuticsEFFECTRegistration effective
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
SMMTSummit TherapeuticsUPLOADUPLOAD
RNACCartesian TherapeuticsSCHEDULE 13D/A13D amendment
RAREUltragenyx Pharmaceutical8-KCurrent report: other events
PMNProMIS NeurosciencesEFFECTRegistration effective
PALIPalisade Bio8-KCurrent report: other events
ORKAOruka TherapeuticsS-3Shelf registration
MLTXMoonLake ImmunotherapeuticsSCHEDULE 13D/A13D amendment
MBRXMoleculin BiotechUPLOADUPLOAD
MAIAMAIA Biotechnology8-KCurrent report: officer / director change
KYTXKyverna TherapeuticsEFFECTRegistration effective
KYTXKyverna Therapeutics424B5Prospectus supplement (offering)
KPRXKiora Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
KODKodiak SciencesSCHEDULE 13GPassive >5% holder (13G)
JBIOJade Biosciences8-KCurrent report: officer / director change
IMUXImmunicS-3Shelf registration
HRMYHarmony Biosciences8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
COYACoya Therapeutics8-KCurrent report: officer / director change · EX-99.1
CLDXCelldex Therapeutics8-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
CLDXCelldex Therapeutics424B5Prospectus supplement (offering)
CINGCingulate8-KCurrent report: officer / director change
ADAGAdagene6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ADAGAdagene6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ADAGAdagene424B5Prospectus supplement (offering)
ADAGAdagene424B5Prospectus supplement (offering)

Wednesday, April 130